Company/Division name | POINT Biopharma Inc. |
Type of work | Manufacturing |
Reshoring category: | Foreign Direct Investment |
Total number of jobs (added or to be added): | 100 |
Year reshoring announced: | 2020 |
Year reshoring implemented or to be implemented: | 2021 |
Domestically, the work will be done: | In-house |
Capital investment ($): | 25 |
Country(ies) from which reshored: | Canada |
City reshored to: | Indianapolis |
State(s) reshored to: | IN |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | radioligands cancer treatments, biopharma |
What domestic positive factors made reshoring more attractive? | Impact on domestic economy, Lead time/Time to market |